Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Granulomatosis with polyangiitis (Wegener's)


Other Names for this Disease

  • Midline granulomatosis
  • Wegener granulomatosis
  • WG
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Newline Maker

How might Wegener's granulomatosis be treated?

Treatment of Wegener's granulomatosis usually includes a combination of glucocorticoids such as prednisone and an immunosuppressive drug such as cyclophosphamide, methotrexate, or azathioprine.[1][2] These medicines may cause serious side effects. Patients should be carefully monitored by a healthcare provider. Other medications which may be prescribed include:[1]

  • Bisphosphonate (Fosamax) to prevent bone loss caused by prednisone
  • Folic acid or folinic acid (leucovorin) -- if you are taking methotrexate
  • Trimethoprim/sulfamethoxazole to prevent lung infections
More detailed information about the treatment of Wegener's granulomatosis can be accessed through the
National Institute of Allergy and Infectious Diseases (NIAID)

Medscape Reference also provides information about the treatment of Wegener's granulomatosis, including a section detailing alternative and/or promising therapies.
Last updated: 7/27/2011

References
  1. Granulomatosis with Polyangiitis (Wegener's). MedlinePlus. March 25, 2014; http://www.nlm.nih.gov/medlineplus/wegenersgranulomatosis.html. Accessed 4/29/2014.
  2. Granulomatosis with polyangiitis (Wegener's) (GPA). Vasculitis Clinical Research Consortium. http://rarediseasesnetwork.epi.usf.edu/vcrc/learnmore/definitions.htm#wg. Accessed 4/29/2014.


Clinical Trials & Research for this Disease

  • The Centers for Mendelian Genomics program is working to discover the causes of rare genetic disorders. For more information about applying to the research study, please visit their website.
  • ClinicalTrials.gov lists trials that are studying or have studied Granulomatosis with polyangiitis (Wegener's). Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Rituximab
Trade Name
(Manufacturer Name)
Rituxan
(Genentech, Inc.)
Indication
The FDA has approved this product to be used in this manner.
For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of pateints with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).
More Information about this product Drug Information Portal
Medline Plus Health Information

Other Names for this Disease
  • Midline granulomatosis
  • Wegener granulomatosis
  • WG
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.